MET Stock Forecast 2025-2026
Distance to MET Price Targets
MET Price Momentum
10 Quality Stocks Worth Considering Now
Researching MetLife (MET) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on MET and similar high-potential opportunities.
Latest MET Stock Price Targets & Analyst Predictions
Based on our analysis of 24 Wall Street analysts, MET has a bullish consensus with a median price target of $96.00 (ranging from $73.00 to $110.00). The overall analyst rating is Strong Buy (8.3/10). Currently trading at $83.05, the median forecast implies a 15.6% upside. This outlook is supported by 12 Buy, 3 Hold, and 1 Sell ratings.
Conversely, the most conservative target is provided by Nigel Dally at Morgan Stanley, suggesting a 12.1% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MET Analyst Ratings
MET Price Target Range
Latest MET Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MET.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 28, 2025 | Morgan Stanley | Nigel Dally | Overweight | Maintains | $109.00 |
| Feb 19, 2025 | Wells Fargo | Elyse Greenspan | Overweight | Maintains | $97.00 |
| Feb 12, 2025 | Keefe, Bruyette & Woods | Ryan Krueger | Outperform | Maintains | $98.00 |
| Feb 7, 2025 | Barclays | Alex Scott | Overweight | Maintains | $95.00 |
| Jan 23, 2025 | BMO Capital | Jack Matten | Market Perform | Initiates | $97.00 |
| Jan 14, 2025 | Wells Fargo | Elyse Greenspan | Overweight | Maintains | $92.00 |
| Jan 7, 2025 | JP Morgan | Jimmy Bhullar | Overweight | Maintains | $88.00 |
| Jan 6, 2025 | Barclays | Alex Scott | Overweight | Maintains | $96.00 |
| Nov 27, 2024 | TD Cowen | Daniel Bergman | Buy | Maintains | $99.00 |
| Nov 5, 2024 | Wells Fargo | Elyse Greenspan | Overweight | Maintains | $93.00 |
| Oct 31, 2024 | Barclays | Alex Scott | Overweight | Maintains | $90.00 |
| Oct 10, 2024 | Wells Fargo | Elyse Greenspan | Overweight | Maintains | $92.00 |
| Oct 9, 2024 | TD Cowen | Daniel Bergman | Buy | Initiates | $97.00 |
| Oct 2, 2024 | Piper Sandler | John Barnidge | Overweight | Maintains | $92.00 |
| Sep 27, 2024 | Jefferies | Suneet Kamath | Buy | Maintains | $95.00 |
| Sep 4, 2024 | Barclays | Alex Scott | Overweight | Initiates | $91.00 |
| Aug 19, 2024 | Morgan Stanley | Nigel Dally | Overweight | Maintains | $85.00 |
| Aug 12, 2024 | Wells Fargo | Elyse Greenspan | Overweight | Maintains | $86.00 |
| Aug 1, 2024 | B of A Securities | Joshua Shanker | Buy | Maintains | $96.00 |
| Jul 23, 2024 | Citigroup | Michael Ward | Buy | Maintains | $89.00 |
MetLife Inc. (MET) Competitors
The following stocks are similar to MetLife based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
MetLife Inc. (MET) Financial Data
MetLife Inc. has a market capitalization of $57.18B with a P/E ratio of 14.1x. The company generates $70.98B in trailing twelve-month revenue with a 6.2% profit margin.
Revenue growth is -1.9% quarter-over-quarter, while maintaining an operating margin of +4.7% and return on equity of +15.3%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
MetLife Inc. (MET) Business Model
About MetLife Inc.
Global provider of insurance and financial services.
The company operates primarily in the life insurance sector, generating revenue through the sale of insurance products, annuities, and employee benefit programs. It serves a diverse clientele including individuals, businesses, and institutions, leveraging a robust network to deliver tailored financial protection solutions.
Established in 1868, MetLife operates across multiple continents and is recognized for its innovative retirement planning and wealth management services. The company has a strong influence in the financial market and is known for its financial stability and reliability.
Company Information
Sector
Financial Services
Industry
Insurance - Life
Employees
45,000
CEO
Mr. Michel Abbas Khalaf
Country
United States
IPO Year
2000
Website
www.metlife.comMetLife Inc. (MET) Latest News & Analysis
AM Best assigned a "bbb+" credit rating to MetLife's newly issued $1 billion subordinated notes, due March 15, 2055, with a stable outlook. Other ratings for MetLife remain unchanged.
MetLife's new subordinated notes have a stable credit rating, indicating solid financial health and manageable leverage, which can enhance investor confidence and influence stock performance.
MET plans to expand its operations throughout Latin America by utilizing technology and adopting an agile startup model.
MET's agile model and tech focus indicate potential for rapid growth in Latin America, attracting investor interest in scalability and market expansion.
Evercore identified stocks likely to perform well in a declining broader market, suggesting potential investment opportunities for risk-averse investors.
Evercore's stock screening signals potential safe havens, indicating opportunities for investors to mitigate risk amid broader market downturns.
MetLife's 2025 U.S. Employee Benefit Trends Study shows declines in holistic health, productivity, and engagement. Employees cite financial concerns as major stressors amid economic uncertainty.
Declining employee health, productivity, and engagement signal potential challenges for companies. Employers may need to enhance benefits, impacting costs and profitability, which affects stock performance.
MetLife launched a new regional business unit, MetLife Xcelerator, in Latin America to enhance embedded insurance and improve financial protection access as part of its New Frontier strategy.
MetLife's new regional unit and Xcelerator platform aim to transform insurance in Latin America, potentially increasing market share and driving growth, which can positively impact stock performance.
MetLife, Inc. declared a Q1 2025 dividend of $0.35516415 per share on its Series A floating rate preferred stock. Ex-dividend date is pending from the NYSE.
MetLife's confirmation of its dividend on preferred stock indicates financial stability and commitment to shareholder returns, potentially boosting investor confidence and stock value.
Frequently Asked Questions About MET Stock
What is MetLife Inc.'s (MET) stock forecast for 2025?
Based on our analysis of 24 Wall Street analysts, MetLife Inc. (MET) has a median price target of $96.00. The highest price target is $110.00 and the lowest is $73.00.
Is MET stock a good investment in 2025?
According to current analyst ratings, MET has 12 Buy ratings, 3 Hold ratings, and 1 Sell ratings. The stock is currently trading at $83.05. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MET stock?
Wall Street analysts predict MET stock could reach $96.00 in the next 12 months. This represents a 15.6% increase from the current price of $83.05. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is MetLife Inc.'s business model?
The company operates primarily in the life insurance sector, generating revenue through the sale of insurance products, annuities, and employee benefit programs. It serves a diverse clientele including individuals, businesses, and institutions, leveraging a robust network to deliver tailored financial protection solutions.
What is the highest forecasted price for MET MetLife Inc.?
The highest price target for MET is $110.00 from at , which represents a 32.5% increase from the current price of $83.05.
What is the lowest forecasted price for MET MetLife Inc.?
The lowest price target for MET is $73.00 from Nigel Dally at Morgan Stanley, which represents a -12.1% decrease from the current price of $83.05.
What is the overall MET consensus from analysts for MetLife Inc.?
The overall analyst consensus for MET is bullish. Out of 24 Wall Street analysts, 12 rate it as Buy, 3 as Hold, and 1 as Sell, with a median price target of $96.00.
How accurate are MET stock price projections?
Stock price projections, including those for MetLife Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
